Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

December 7, 2018

Primary Completion Date

September 1, 2023

Study Completion Date

September 1, 2023

Conditions
Metastatic Prostate CancerAndrogen Deprivation Therapy
Interventions
DRUG

GnRH agonist

Zoladex is a gonadotropin-releasing hormone agonist, or GnRH-A. It is an implant that is injected under the skin (subcutaneously). The implant gradually dissolves and releases the drug over the time between injections. There are two dosages of Zoladex: Zoladex 10.8 mg, which is injected once every 3 months, and Zoladex 3.6 mg, which is injected once a month.

Trial Locations (1)

98108

Veterans Affairs Puget Sound Health Care System, Seattle

All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

University of Washington

OTHER

lead

Seattle Institute for Biomedical and Clinical Research

OTHER

NCT03867357 - Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia | Biotech Hunter | Biotech Hunter